Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)
Tryfon Zarganes‐Tzitzikas(University of Groningen), Alexander Dömlingꝉ(University of Groningen), Dobrosława Krzemień(Jagiellonian University), Tad A. Holak(Jagiellonian University), Markella Konstantinidou(University of California, San Francisco), Grzegorz Dubin(Jagiellonian University), Krzysztof M. Żak(Jagiellonian University), Yongzhi Gao(University of Groningen)
Cited by 104
Related Papers
Covalent inhibitors: a rational approach to drug discovery
|RSC Medicinal Chemistry|2020|375
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
|Oncotarget|2017|308
PROTACs– a game-changing technology
|Expert Opinion on Drug Discovery|2019|159
Molecular glues for protein-protein interactions: Progressing toward a new dream
|Cell chemical biology|2024|139
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
|Angewandte Chemie International Edition|2017|133